Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
N Von Bubnoff, PW Manley, J Mestan, J Sanger… - Blood, 2006 - ashpublications.org
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
N von Bubnoff, PW Manley, J Mestan, J Sanger… - Blood, 2006 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> In advanced-phase chronic myeloid leukemia
(CML), resistance to imatinib mesylate is associated with point mutations in the BCR-ABL …
(CML), resistance to imatinib mesylate is associated with point mutations in the BCR-ABL …
[PDF][PDF] Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
N von Bubnoff, PW Manley, J Mestan, J Sanger… - BLOOD, 2006 - academia.edu
The tyrosine kinase inhibitor imatinib mesylate (Gleevec; Novartis Pharma, Basel,
Switzerland) fundamentally changed the standard of care for the treatment of chronic …
Switzerland) fundamentally changed the standard of care for the treatment of chronic …
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
N Von Bubnoff, PW Manley, J Mestan, J Sanger… - …, 2006 - research.uni-luebeck.de
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
N von Bubnoff, PW Manley, J Mestan, J Sanger… - Blood, 2006 - europepmc.org
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
N von Bubnoff, PW Manley, J Mestan, J Sanger… - …, 2006 - pubmed.ncbi.nlm.nih.gov
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
[引用][C] Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
N VON BUBNOFF, PW MANLEY, J MESTAN… - Blood, 2006 - pascal-francis.inist.fr
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated
with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) CNRS Inist Pascal-Francis …
with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) CNRS Inist Pascal-Francis …
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
N von Bubnoff, PW Manley, J Mestan, J Sanger… - 2006 - mediatum.ub.tum.de
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
[HTML][HTML] Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib …
N von Bubnoff, PW Manley, J Mestan, J Sanger… - Blood, 2006 - Elsevier
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …
[引用][C] BCR-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib …
VON BUBNOFF - Blood, 2006 - cir.nii.ac.jp
BCR-Abl resistance screening predicts a limited spectrum of point mutations to be
associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) | CiNii …
associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) | CiNii …